olodanrigan   Click here for help

GtoPdb Ligand ID: 8374

Synonyms: [S]-enantiomer of EMA400 [9] | [S]-enantiomer of PD-126,055 | EMA-401 | EMA401
PDB Ligand
Compound class: Synthetic organic
Comment: Olodanrigan (EMA401) is reported as a selective antagonist of the angiotensin type II receptor (AT2R) [6,9]. The compound is being assessed as a novel therapy for neuropathic pain [3].
Note that PubChem CID 23683656 refers to the potassium salt and that the sodium salt was used in [9].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

olodanrigan is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 76.07
Molecular weight 507.2
XLogP 5.36
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES COc1ccc2c(c1OCc1ccccc1)CC(N(C2)C(=O)C(c1ccccc1)c1ccccc1)C(=O)O
Isomeric SMILES COc1ccc2c(c1OCc1ccccc1)C[C@H](N(C2)C(=O)C(c1ccccc1)c1ccccc1)C(=O)O
InChI InChI=1S/C32H29NO5/c1-37-28-18-17-25-20-33(31(34)29(23-13-7-3-8-14-23)24-15-9-4-10-16-24)27(32(35)36)19-26(25)30(28)38-21-22-11-5-2-6-12-22/h2-18,27,29H,19-21H2,1H3,(H,35,36)/t27-/m0/s1
InChI Key GHBCIXGRCZIPNQ-MHZLTWQESA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Chakrabarty A, Blacklock A, Svojanovsky S, Smith PG. (2008)
Estrogen elicits dorsal root ganglion axon sprouting via a renin-angiotensin system.
Endocrinology, 149 (7): 3452-60. [PMID:18388195]
2. Finnerup NB, Baastrup C. (2014)
Angiotensin II: from blood pressure to pain control.
Lancet, 383 (9929): 1613-4. [PMID:24507378]
3. McCarthy T. (2014)
Development of EMA401 as an orally-administered, highly-selective angiotensin II type 2 receptor antagonist for the treatment of neuropathic pain.
J Peripher Nerv Syst, 19 Suppl 2: S13-4. [PMID:25269730]
4. Murgasova R, Carreras ET, Suetterlin-Hachmann M, da Silva Torrao LR, Kittelmann M, Alexandra V, Fredenhagen A. (2020)
Non-clinical characterization of the disposition of EMA401, a novel small molecule angiotensin II type 2 receptor (AT2R) antagonist.
Biopharm Drug Dispos, 41 (4-5): 166-183. [PMID:32190910]
5. Patil J, Schwab A, Nussberger J, Schaffner T, Saavedra JM, Imboden H. (2010)
Intraneuronal angiotensinergic system in rat and human dorsal root ganglia.
Regul Pept, 162 (1-3): 90-8. [PMID:20346377]
6. Rice AS, Dworkin RH, McCarthy TD, Anand P, Bountra C, McCloud PI, Hill J, Cutter G, Kitson G, Desem N et al.. (2014)
EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.
Lancet, 383 (9929): 1637-47. [PMID:24507377]
7. Smith MT. (2013)
Method of treatment or prophylaxis of inflammatory pain.
Patent number: US8551950. Assignee: Spinifex Pharmaceuticals Pty Ltd. Priority date: 20/03/2006. Publication date: 08/10/2013.
8. Smith MT, Wyse BD. (2010)
Method of treatment or prophylaxis.
Patent number: US7795275. Assignee: Uniquest Pty Limited. Priority date: 24/12/2004. Publication date: 14/09/2010.
9. Smith MT, Wyse BD, Edwards SR. (2013)
Small molecule angiotensin II type 2 receptor (AT₂R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats.
Pain Med, 14 (5): 692-705. [PMID:23489258]